These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8960716)

  • 41. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
    Salloway S; Ferris S; Kluger A; Goldman R; Griesing T; Kumar D; Richardson S;
    Neurology; 2004 Aug; 63(4):651-7. PubMed ID: 15326237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
    Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
    Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II trial of huperzine A in mild to moderate Alzheimer disease.
    Rafii MS; Walsh S; Little JT; Behan K; Reynolds B; Ward C; Jin S; Thomas R; Aisen PS;
    Neurology; 2011 Apr; 76(16):1389-94. PubMed ID: 21502597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.
    Thal LJ; Grundman M; Berg J; Ernstrom K; Margolin R; Pfeiffer E; Weiner MF; Zamrini E; Thomas RG
    Neurology; 2003 Dec; 61(11):1498-502. PubMed ID: 14663031
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
    Feldman HH; Lane R;
    J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1056-63. PubMed ID: 17353259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
    Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
    JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
    Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
    Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.
    Dunbar F; Zhu Y; Brashear HR
    Clin Ther; 2006 Mar; 28(3):365-72. PubMed ID: 16750451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
    Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
    Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease.
    Wong WJ; Liu HC; Fuh JL; Wang SJ; Hsu LC; Wang PN; Sheng WY
    Dement Geriatr Cogn Disord; 1999; 10(4):289-94. PubMed ID: 10364647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.
    Mulnard RA; Cotman CW; Kawas C; van Dyck CH; Sano M; Doody R; Koss E; Pfeiffer E; Jin S; Gamst A; Grundman M; Thomas R; Thal LJ
    JAMA; 2000 Feb; 283(8):1007-15. PubMed ID: 10697060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rivastigmine for dementia associated with Parkinson's disease.
    Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
    N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.
    Schneider LS; DeKosky ST; Farlow MR; Tariot PN; Hoerr R; Kieser M
    Curr Alzheimer Res; 2005 Dec; 2(5):541-51. PubMed ID: 16375657
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
    Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
    Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
    Homma A; Atarashi H; Kubota N; Nakai K; Takase T
    J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C
    Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.